Patents Examined by Iqbal H Chowdhury
  • Patent number: 11162105
    Abstract: The present invention provides engineered purine nucleoside phosphorylase (PNP) enzymes, polypeptides having PNP activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PNP enzymes are also provided. The present invention further provides compositions comprising the PNP enzymes and methods of using the engineered PNP enzymes. The present invention finds particular use in the production of pharmaceutical compounds.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: November 2, 2021
    Assignee: Codexis, Inc.
    Inventors: Scott J. Novick, Nikki Dellas, Vesna Mitchell, Da Duan, Jovana Nazor, Oscar Alvizo, Auric Anthony Sowell-Kantz, Jeffrey C. Moore, Mark Huffman, Agustina Rodriguez-Granillo, Deeptak Verma, Nicholas M. Marshall, Jay Russell, Keith A. Canada
  • Patent number: 11155837
    Abstract: Genetically modified microorganisms that have the ability to convert carbon substrates into chemical products such as 1,4-BDO are disclosed. For example, genetically modified methanotrophs that are capable of generating 1,4-BDO at high titers from a methane source are disclosed. Methods of making these genetically modified microorganisms and methods of using them are also disclosed.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: October 26, 2021
    Assignee: PRECIGEN, INC.
    Inventors: Xinhua Zhao, Tina Huynh, Jeffrey Orth, Lily Yuin Chao, James Kealey
  • Patent number: 11155790
    Abstract: This invention relates to mutant enzymes with enhanced properties and processes for oxidation of organic compound substrates using such enzymes.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: October 26, 2021
    Inventors: Luet Lok Wong, Stephen Graham Bell, Christopher Whitehouse
  • Patent number: 11149257
    Abstract: The present invention provides an ascorbate peroxidase mutant MaAPX1M36K and an application thereof, belonging to the technical field of biotechnology. An amino acid sequence of the mutant MaAPX1M36K of the present invention is shown in SEQ ID NO. 3. In the present invention, the mutant MaAPX1M36K reconstruction protein is obtained by the method of prokaryotic expression. It is found that the mutant MaAPX1M36K improves catalytic efficiency by nearly 5 times, providing a technical reference for further study and application of APX1.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: October 19, 2021
    Assignee: SOUTH CHINA BOTANICAL GARDEN, CHINESE ACADEMY OF SCIENCES
    Inventors: Xuewu Duan, Lu Xiao, Guoxiang Jiang, Yueming Jiang, Huiling Yan, Zhiwei Li, Jing Zeng, Xiaochun Ding
  • Patent number: 11149280
    Abstract: Organisms resistant to horizontal gene transfer (HGT), and compositions and methods of use thereof are provided. The organisms are typically genomically recoded organisms (GRO), typically cells, having a genome in which at least one endogenous codon has been eliminated by reassignment of the codon to a synonymous or non-synonymous codon. The GRO typically include a recombinant expression construct for expression of at least one element of a ribosomal rescue pathway, typically lacking the eliminated codon. Typically, the disclosed cells are resistant to completed transfer and/or expression of a horizontally transferred genetic element (HTGE) from another organism compared a corresponding cell having a genome wherein the eliminated codon has not been eliminated. In some embodiments, the organism from which the HTGE is being transferred is a bacterium or a virus.
    Type: Grant
    Filed: November 30, 2020
    Date of Patent: October 19, 2021
    Assignee: YALE UNIVERSITY
    Inventors: Farren Isaacs, Natalie Ma, Jesse Rinehart, Colin Hemez
  • Patent number: 11136565
    Abstract: Provided herein are modified Archaeal family B polymerases derived from the Archaeal microorganism Pyrococcus abyssi that exhibit improved incorporation of nucleotide analogues utilized in DNA sequencing.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: October 5, 2021
    Assignee: SINGULAR GENOMICS SYSTEMS, INC.
    Inventors: Souad Naji, Carl W. Fuller, Eli Glezer, Andrew Spaventa
  • Patent number: 11136569
    Abstract: Provided are a novel isoamylase improved in optimum temperature, and more specifically, improved in heat resistance, and a process for producing the isoamylase. An isoamylase having at least one amino acid mutation selected from the group consisting of D268A, M277I, A549P, A554P and A580T in an isoamylase consisting of an amino acid sequence represented by SEQ ID No: 1 or an isoamylase consisting of the amino acid sequence represented by SEQ ID No: 1 and having deletion, substitution or insertion of one to several amino acid residues.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: October 5, 2021
    Assignee: GODO SHUSEI CO., LTD.
    Inventors: Masahiro Baba, Ryoko Sano, Shun Ogawa, Hirofumi Horiguchi, Jun Yoshikawa
  • Patent number: 11124825
    Abstract: A method for identifying any of the presence, location and phasing of modified cytosines (C) in long stretches of nucleic acids is provided. In some embodiments, the method may comprise (a) reacting a first portion of a nucleic acid sample containing at least one C and/or at least one modified C with a DNA glucosyltransferase and a cytidine deaminase to produce a first product and/or reacting a second portion of the sample with a dioxygenase, optionally a DNA glucosyltransferase and a cytidine deaminase to produce a second product and; (b) comparing the sequences from the first and optionally the second product obtained in (a), or amplification products thereof, with each other and/or an untreated reference sequence to determine which Cs in the initial nucleic acid fragment are modified. A modified TET methylcytosine dioxygenase with improved efficiency compared to unmodified TET2 at converting methylcytosine to carboxymethylcytosine is also provided.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: September 21, 2021
    Assignee: New England Biolabs, Inc.
    Inventors: Romualdas Vaisvila, Zhiyi Sun, Shengxi Guan, Lana Saleh, Laurence Ettwiller, Theodore B. Davis
  • Patent number: 11124811
    Abstract: A method of producing ?-hydromuconic acid using a metabolic pathway of a microorganism is disclosed. The method of producing ?-hydromuconic acid includes the step of culturing at least one type of microorganism having a capacity to produce ?-hydromuconic acid, selected from the group consisting of microorganisms belonging to the genus Escherichia, microorganisms belonging to the genus Pseudomonas, microorganisms belonging to the genus Hafnia, microorganisms belonging to the genus Bacillus, microorganisms belonging to the genus Cupriavidus, microorganisms belonging to the genus Acinetobacter, microorganisms belonging to the genus Alcaligenes, microorganisms belonging to the genus Delftia, and microorganisms belonging to the genus Shimwellia.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: September 21, 2021
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Kyohei Isobe, Kenji Kawamura, Masateru Ito, Katsushige Yamada
  • Patent number: 11124783
    Abstract: Bridge helix-modified variant Cas9 proteins having improved DNA cleavage selectivity in comparison to wild type versions of the Cas9 proteins, nucleic acids encoding the variant proteins, host cells containing the nucleic acids, and methods of their use.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: September 21, 2021
    Assignee: The Board of Regents of the University of Oklahoma
    Inventor: Rakhi Rajan
  • Patent number: 11104886
    Abstract: The present invention relates a polypeptide having kaurenoic acid 13-hydroxylase activity, which polypeptide comprises an amino acid sequence which, when aligned with a kaurenoic acid 13-hydroxylase comprising the sequence set out in SEQ ID NO: 1 or SEQ ID NO: 3, comprises at least one substitution of an amino acid corresponding to any of amino acids at positions 136, 248, 336 or 403, said positions being defined with reference to SEQ ID NO: 1 or SEQ ID NO: 3 and wherein the polypeptide has one or more modified properties as compared with a reference polypeptide having kaurenoic acid 13-hydroxylase activity. A polypeptide of the invention may be used in a recombinant host for the production of steviol or a steviol glycoside.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: August 31, 2021
    Assignee: DSM IP ASSETS B.V.
    Inventors: Johannes Gustaaf Ernst Van Leeuwen, Priscilla Zwartjens, Viktor Marius Boer
  • Patent number: 11104920
    Abstract: Methods for the recovery of lipids, sugars, and proteins from microbial biomass by enzymatic digestion are disclosed. The methods involve treating microalgae with a fungal acid protease, or with a mixture of at least one protease and at least one amylase.
    Type: Grant
    Filed: July 20, 2020
    Date of Patent: August 31, 2021
    Assignee: The University of Toledo
    Inventors: Agasteswar Vadlamani, Patricia A. Relue, Sridhar Viamajala, Heng Shao, Sasidhar Varanasi
  • Patent number: 11098330
    Abstract: A method for producing ergothioneine at a low cost in large quantities and a bacterium for use in said method are provided. A method for producing ergothioneine or a related substance thereof, or a mixture thereof, comprising culturing a bacterium belonging to the family Enterobacteriaceae having the ergothioneine-producing ability in a culture medium, and collecting ergothioneine or a related substance thereof, or a mixture thereof, from the culture medium or from the cells obtained by culture, wherein said bacterium is the one which is modified so as to have a reduced activity of a protein comprising a core sequence region comprising 5 amino acid residues: Ser-Arg-Gly-Arg-Thr (SEQ ID NO:7) as a part thereof; and a bacterium belonging to the family Enterobacteriaceae having the ergothioneine-producing ability modified so as to have a reduced activity of a protein comprising a core sequence region comprising 5 amino acid residues: Ser-Arg-Gly-Arg-Thr (SEQ ID NO:7) as a part thereof.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: August 24, 2021
    Assignee: NAGASE & CO., LTD.
    Inventors: Takeshi Nakatani, Nanami Nakashima
  • Patent number: 11078465
    Abstract: The present disclosure discloses an alcohol dehydrogenase mutant and application thereof in synthesis of diaryl chiral alcohols, and belongs to the technical field of bioengineering. The alcohol dehydrogenase mutant of the present disclosure has excellent catalytic activity and stereoselectivity, and may efficiently catalyze the preparation of a series of chiral diaryl alcohols in R- and S-configurations. By coupling alcohol dehydrogenase of the present disclosure to glucose dehydrogenase or formate dehydrogenase, the synthesis of chiral diaryl alcohol intermediates of various antihistamines may be achieved. Compared with the prior art, a method for preparing diaryl chiral alcohols through asymmetric catalytic reduction using the alcohol dehydrogenase of the present disclosure has the advantages of simple and convenient operation, high substrate concentration, complete reaction and high product purity, and has great industrial application prospects.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: August 3, 2021
    Assignee: JIANGNAN UNIVERSITY
    Inventors: Ye Ni, Yue Wang, Wei Dai, Guochao Xu, Jieyu Zhou
  • Patent number: 11066690
    Abstract: The present invention relates to FAD-GDH consisting of the amino acid sequence of SEQ ID NO: 1 or 3, an amino acid sequence having an identity of 70% or more with the amino acid sequence of SEQ ID NO: 1 or 3, or an amino acid sequence having a deletion, substitution or addition of one or several amino acids in the amino acid sequence (the amino acid sequence of SEQ ID NO: 1 or the amino acid sequence having an identity of 70% or more with the amino acid sequence of SEQ ID NO: 1); having an amino acid substitution at the position(s) corresponding to the following amino acid(s): the amino acid at the 175th position in the amino acid sequence of SEQ ID NO: 1, the amino acid at the 214th position in the amino acid sequence of SEQ ID NO: 1, the amino acid at the 192nd position in the amino acid sequence of SEQ ID NO: 1, the amino acid at the 212th position in the amino acid sequence of SEQ ID NO: 1, the amino acid at the 218th position in the amino acid sequence of SEQ ID NO: 1, and/or the amino acid at the 226th
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: July 20, 2021
    Assignee: KIKKOMAN CORPORATION
    Inventors: Yousuke Masakari, Chiaki Hara
  • Patent number: 11060077
    Abstract: The invention is used in the field of enzyme technology. The invention relates to lipases and to the production thereof, the amino acid sequence of which has been modified in particular with regard to the use thereof in detergents and cleaning agents, all sufficiently similar lipases having a corresponding modification and nucleic acids coding for them. The invention further relates to methods and uses of said lipases and to agents containing them, in particular detergents and cleaning agents.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: July 13, 2021
    Assignee: Henkel AG & Co. KGaA
    Inventors: Daniela Herbst, Timothy O'Connell, Nina Mussmann, Renée Charlott Eichstaedt, Claudia Lindner, Georgette Koerfer, Mehdi Davari Dolatabadi, Ljubica Vojcic, Ulrich Schwaneberg
  • Patent number: 11046940
    Abstract: The present disclosure provides non-natural reverse transcriptases for conducting reverse transcription. The non-natural reverse transcriptases herein may have increased thermostability and can conduct reverse transcription more efficiently than natural reverse transcriptases.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: June 29, 2021
    Assignee: Solis BioDyne OU
    Inventor: Olev Kahre
  • Patent number: 11046988
    Abstract: The present invention relates to a process for the modification of a glycoprotein, using a ?-(1,4)-N-acetylgalactosaminyltransferase or a mutant thereof. The process comprises the step of contacting a glycoprotein comprising a glycan comprising a terminal GlcNAc-moiety, in the presence of a ?-(1,4)-N-acetylgalactosaminyltransferase or a mutant thereof, with anon-natural sugar-derivative nucleotide. The non-natural sugar-derivative nucleotideis according to formula (3), wherein A is selected from the group consisting of —N3; —C(O)R3; —C?C—R4; —SH; —SC(O)R8; —SC(V)OR8, wherein V is O or S; —X wherein X is selected from the group consisting of F, Cl, Br and I; —OS(O)2R5; an optionally substituted C2-C24 alkyl group; an optionally substituted terminal C2-C24 alkenyl group; and an optionally substituted terminal C3-C24 alkenyl group.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: June 29, 2021
    Assignee: SYNAFFIX B.V.
    Inventors: Anna Agnieszka Wasiel, Floris Louis Van Delft, Sander Sebastiaan Van Berkel
  • Patent number: 11046990
    Abstract: The present invention relates to recombinant yeast, in which the productivity of ginsenoside is enhanced by overexpressing CPR5, PDI1, or ERO1 in yeast having the productivity of ginsenosides; a method for preparing the yeast; and a method for producing ginsenosides using the yeast.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: June 29, 2021
    Inventors: Sun-Chang Kim, Ju Young Lee, In Seung Jang, Seohyun Kim, Jong Geon Jegal
  • Patent number: 11040077
    Abstract: Disclosed herein are compositions and methods for using human-derived Janthinobacterium lividum. Compositions improve skin health. Methods may include applying human-derived Janthinobacterium lividum over a host or host area, such as skin or mucosa, to minimize the presence of one or more microbes, maximize therapeutic effects, and/or improve health. A method to minimize a pathogenic microbe may include applying to a surface a composition including human-derived Janthinobacterium lividum and an acceptable carrier. Compositions and methods may include a prebiotic to maximize growth and/or metabolites. Compositions and methods may include human-derived Janthinobacterium lividum metabolites, such as violacein, prodigiosin, indole-3-carboxaldehyde, and lantibiotics, and/or other Postbiotics.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: June 22, 2021
    Assignee: DermBiont, Inc.
    Inventors: Robert M. Brucker, Xuecheng Zhang, Ida Lister, Sanjay Jain